The Filing Desk

NRC Health

NRC · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

NRC · Last close · November 19, 2026
$24.99
Value NRC Health yourself

NRC Health's revenue fell 4.0% to $137 million in fiscal 2025. Its operating margin was 16.4%, down from 24.6% a year earlier. Free cash flow was $16 million, down 17.9%. It paid out $31 million in dividends and buybacks, 198% of free cash flow. The diluted share count fell 5.7%.

NRC Health Latest fiscal year ended December 31, 2025 10-K filed March 5, 2026 · 0001437749-26-007002 Updated
Revenue
$137M
4.0%
Operating margin
16.4%
8.2 pts
Net income
$12M
53.2%
Free cash flow
$16M
17.9%
Return on capital
16.4%
15.2 pts
Market cap
$547M
Nov 19 close
P/E
—
 

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. NRC Health's 2025 annual report shows earnings per share of 50 dollars, which can't be right: net income divided by shares is about 52 cents. Earnings per share is left blank for every year until the filing is corrected.

Charts show fiscal years, from the 10-K filings.

What NRC Health does

NRC Health sells subscription-based tools that help healthcare organizations learn what patients, consumers and employees think. It collects survey feedback and other self-reported information, analyzes it, and gives hospitals and health systems reports and workflow tools to act on it. Its customers are spread across the United States.

It groups its digital solutions in four categories: Patient Experience, Consumer Experience, Employee Experience and Market Experience. They cover patient surveys, including surveys that meet federal CAHPS rules, discharge calls, online reputation and star ratings, employee engagement, and a yearly consumer survey of about 300,000 people. Revenue comes mostly from recurring contracts that customers renew each year. NRC Health says it competes in a market with many rivals and new entrants. Its ten largest customers made up 20% of revenue in 2025.

The company was founded in 1981 and is based in Lincoln, Nebraska. As of December 31, 2025, it had 357 associates, most of whom work remotely.

Its biggest risks, as it describes them

  • Customers may not renew contracts, may buy less, or may pay lower prices, and it may lose key customers.
  • It faces strong competition and possible price pressure in a crowded market.
  • Its customers are all in healthcare, so industry rule changes, downturns and consolidation affect it directly.
  • Problems collecting the survey data its business relies on.
  • Its principal shareholders effectively control the company.
From NRC Health's annual report on Form 10-K, filed March 5, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2016 to 2025, net income fell 6.1% a year; the filings' structured data doesn't give diluted earnings per share.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red. Where the filings' structured data doesn't give a year's earnings per share, the column is blank.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments5425744
Debt incl. finance leases2722376379
Net debt (negative means net cash)−27−3305875
Net debt to EBITDA——0.7x1.4x2.5x
Debt to equity0.3x0.3x0.8x2.0x5.7x
Interest coverage30.2x38.5x46.5x13.6x4.7x
Current ratio1.8x1.3x0.7x0.6x0.6x
Quick ratio1.8x1.3x0.7x0.6x0.6x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project NRC Health's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $98,160 of NRC Health shares on the open market, and none sold any.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Feb 17, 2026Shane R HarrisonEVP & Chief Financial OfficerBought8,000$12.27$98,160Form 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score6 of 85 of 85 of 8
Rule of 4013.1%9.7%7.5%
Altman Z''1.450.880.03
Accruals ratio−5.7%−7.7%−11.1%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positivePassPassPass
Cash from operations is positivePassPassPass
Return on assets rosePassFailFail
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsFailFailFail
Current ratio roseFailFailPass
Share count didn't risePassPassPass
Gross margin rose———
Revenue rose relative to assetsPassPassFail
F-score6 of 85 of 85 of 8
Companies that report no gross profit are scored on the other eight.

Compare

Put NRC Health side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
NRC HealthFY25−4.0%16.4%11.5%16.4%2.5x5
CareCloudFY258.7%9.4%19.7%21.5%−0.1x5Compare
OptimizeRxFY2518.8%10.7%17.1%6.4%0.2x8Compare
HeartFlowFY2539.9%−36.4%−33.5%———Compare
SOPHiA GENETICSFY2518.6%−91.8%−47.2%−207.1%—2Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue109118120128133148152149143137
Revenue growth6.9%7.5%1.8%6.9%4.1%11.0%2.4%−2.0%−3.7%−4.0%
Gross profit——————————
Research and development——————————
Operating income31343543435046403523
Net income20233032373832312512
Diluted EPS (US$)——————————
Diluted shares (millions)———26262625252422
Cash flow
Cash from operations27284041414636383526
Capital expenditure45654610161511
Free cash flow23243436374126221916
Dividends paid2917173110921361211
Share buybacks00000428193120
Acquisitions0000030050
Stock-based compensation2221111103
Balance sheet at fiscal year end
Cash and short-term investments33351314355425744
Debt incl. finance leases413935322722376379
Total assets121127108111133158130122132135
Total liabilities3837897869725874101121
Shareholders' equity83901933648572493114
Margins and ratios
Gross margin——————————
Operating margin28.5%29.1%29.5%33.6%32.0%34.0%30.7%26.9%24.6%16.4%
Net margin18.8%19.5%25.1%25.3%28.0%25.3%21.0%20.8%17.3%8.4%
Free cash flow margin20.9%20.0%28.3%28.3%27.5%27.6%17.4%15.0%13.4%11.5%
Rule of 40 (growth + FCF margin)27.8%27.5%30.1%35.3%31.6%38.6%19.9%13.1%9.7%7.5%
Return on capital44.8%41.8%60.3%69.3%66.1%64.5%54.1%41.8%31.6%16.4%
Return on equity26.1%26.6%55.1%124.7%76.7%50.1%40.4%51.2%61.8%51.2%
Return on assets16.5%18.5%25.5%29.6%30.5%25.8%22.1%24.5%19.4%8.7%
Net debt to EBITDA−0.8x−0.9x0.6x0.4x———0.7x1.4x2.5x
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: NRC Health's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with NRC Health.